03.31.22 -- Making Waves In Cell Therapy
03/31/22 Life Science Leader Newsletter
Source: lifescienceleader.com
📰 Kleanthis Xanthopoulos News
Kleanthis Xanthopoulos News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Kleanthis Xanthopoulos. Real-time updates on events, politics, business and more.
03.12.22 -- New Pod Episodes: Gene Therapy with AAV Vectors and NK Cell Therapy Accessibility
03/12/22 Pharmaceutical Online Newsletter
Source: pharmaceuticalonline.com
03.08.22 -- New Pod Episodes: Gene Therapy with AAV Vectors and NK Cell Therapy Accessibility
03/08/22 Life Science Leader Newsletter
Source: lifescienceleader.com
03.07.22 -- New Pod Episodes: Gene Therapy with AAV Vectors and NK Cell Therapy Accessibility
03/07/22 Clinical Leader Newsletter
Source: clinicalleader.com
03.07.22 -- From CRO Executive To Biopharma CEO
03/07/22 Life Science Leader Newsletter
Source: lifescienceleader.com
Art Of The Startup — Making New Waves
As Shoreline’s chairman, CEO, and cofounder, Dr. Kleanthis Xanthopoulos draws on his experience of several decades, starting and running...
Source: lifescienceleader.com
San Diego biotech chases 'one-size-fits-all' cancer drugs - The San Diego Union-Tribune
Shoreline Biosciences is one of several local companies engineering immune cells to efficiently seek and destroy cancer cells.
Source: sandiegouniontribune.com
San Diego biotech chases 'one-size-fits-all' cancer drugs
Shoreline Biosciences is one of several local companies engineering immune cells to efficiently seek and destroy cancer cells.
Source: delmartimes.net
Beigene expands into cancer cell therapy with Shoreline pact
Published June 9, 2021 National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr. Dive Brief: Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs with which its had success. Under a deal announced...
Source: biopharmadive.com